Results revealed that amongst these BRCA1 mutation carriers, those who had overexpression of the cytoplasmic, tumor specific forms of cyclin E (i.e., LMWE forms) by immunohistochemistry (IHC) (Figure 1G) had significantly shorter time to recurrence compared to those patients whose tumors had low or just nuclear expression of cyclin E (Figure 1G,H). The gene discussed is CCNE1; the disease is neoplasm.